Just sold my shares in Merant. (I know there is probably a few pence more in it. BUT, BUT BUT!!!!


Bought with it some more Bespac. I think it should go on the following information#, but spread is large.

2004 2005
Broker Date Rec Pre-tax ( ) EPS ( p ) DPS ( p ) Pre-tax ( ) EPS( p ) DPS( p )
Investec Securities 27 - 01 - 04 BUY 10.22 26.70 19.10 10.95 28.61 19.10
Seymour Pierce Ltd 01 - 03 - 04 OVAL 7.10 18.60 19.10 10.20 26.60 19.10
Numis Securities Ltd 26 - 02 - 04 BUY 12.00 32.80 15.00 40.00
Nomura Research Institute 02 - 02 - 04 BUY 13.00 35.50 19.10 23.00 62.80 19.10
Dryden Wealth Management Ltd 20 - 01 - 04 HOLD

Strong Buy Buy Weak Buy Weak Buy/Hold Hold Weak Sell/Hold Weak Sell Sell Strong Sell
0 3 0 0 1 0 0 0 1





RPT Bespak drug-delivery deal nears European approval, shares rise (Repeating to clarify nature of deal, adds share price other background) LONDON (AFX) - Bespak PLC said the European Medicines Evaluation Agency had accepted a filing by Pfizer Inc and Aventis SA who are both seeking rights to market Exubera, a diabetes treatment which is inhaled in powdered form. Bespak said it will manufacture the drug delivery device under an arrangement with Nektar Therapeutics, Inc, a US company which developed both Exubera and the means of delivering it. In a statement, Bespak said the timing of full scale production is as yet unknown and will depend in part on the speed of the regulatory review process. Pfizer and Aventis are seeking approval to market Exubera to adult patients with Type 1 and Type 2 diabetes. At 8.20 am Bespak was among the best performing small-cap stocks in the London market, gaining 22-1/2 pence, or 4.2 pct, to 557-1/2.

Fred.
How do you thing the falling Dollar will effect they sales.

Up 16p today, anybody know why , apart from a few buys.

aldwickk Sorry for not responding. Don't really know. Depends whether the deal or arrangements with Nektar are in form of licence or not. Not sure what proportion of sales ill be in the US.

Up 5p this morning on no volume and no news.

back to top

Bespak PLC
16 December 2004


SCHEDULE 10

NOTIFICATION OF MAJOR INTERESTS IN SHARES

1) Name of company: Bespak plc

2) Name of shareholder having a major interest: Aviva plc and its subsidiary,
Morley Fund Management Limited

3) Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18: Not stated

4) Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them:

BNY Norwich Union Nominees Limited - 347,402 (material)

Chase GA Group Nominees Limited - 1,118,606 (material)

CUIM Nominee Limited - 439,822 (material)

5) Number of shares/amount of stock acquired: 37,999

6) Percentage of issued class: 0.142

7) Number of shares/amount of stock disposed:

8) Percentage of issued class:

9) Class of security: Ordinary

10) Date of transaction: 14 December 2004

11) Date company informed: 16 December 2004

12) Total holding following this notification: 1,905,830

13) Total percentage holding of issued class following this notification: 7.11

14) Any additional information: Total shares in issue - 26,805,889

15) Name of contact and telephone number for queries: Louise Scott 01908 525240

16) Name and signature of authorised company official responsible for making
this notification: Louise Scott, Company Secretary

Date of notification : 16 December 2004

LONDON (AFX) - Bespak PLC said it is looking for acquisitions to reduce the company's reliance on components sold to pharmaceutical companies, as the medical device maker reported a drop in first-half profit.

Pretax profit fell to 1.8 mln stg from 2.9 mln last year, dented by a 3.9 mln charge on the closure of a US manufacturing facility. After costs, pretax rose rose 16 pct to 5.7 mln stg.

Sales fell 4 pct to 38.9 mln stg in the 26 weeks to Oct 30, and the company said it will maintain its interim dividend at 7 pence.

The company said the closure of the US plant should improve on-going operating profit by approximately 700,00 stg a year, after further estimated exceptional cash costs of 2 mln stg.

'The Group has performed very well in the first half. Closing the Cary facility removes an under-performing part of the business, and news about the Exubera(R) filing is encouraging,' Mark Throdahl, chief executive said.

Bespak said Pfizer recently announced it is in the final stages of preparing an NDA for Exubera(R), for which its manufactures the inhalation device.

'We are now turning our attention to acquiring specialty medical businesses that play to our strengths and enable us to generate more consistent sales growth.'

The company said it is looking to boost organic growth with selective acquisitions that either infill current businesses or take the group into new, but related, product areas. Acquisitions will initially be financed from cash resources, it added.

It hopes that the addition of businesses which manufacture specialty devices and other products specified by clinicians will reduce its reliance on components sold to pharmaceutical companies, which often entail long development programmes.

newsdesk@afxnews.com

ab

When they all said this was down and out I said buy at 523P on USA potential.

GO YOU LITTLE DARLIN'